ILMNIllumina, Inc.

$224.91

$91.0052 weeks$225.01

Price

$224.91+136%1Y

1M+14%1Y+136%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Above average

7/10

Value16

Quality93

Momentum82

Growth45

Strongest Quality, weakest Value · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

We are a global leader in sequencing- and array-based solutions for genetic and genomic analysis. Our products and services serve customers in a wide range of markets, enabling the adoption of genomic solutions in research and clinical settings. We were incorporated in California in April 1998 and reincorporated in Delaware in July 2000.

In the company’s own words · 10-K filed Feb 12, 2026 · SEC EDGAR

P/E (TTM)42.0

Market Cap$24.50B

1Y Return+136%

5Y Return-53%

Business segments

Q1 2026 · $1.09B

The company’s own SEC segment disclosure.

United States And Canada$590.0M54%
EMEA$356.0M33%
Asia Pacific$93.0M9%
CN$52.0M5%

Illumina, Inc. (ILMN) reported revenue of $1.16B in Q2 2026 (quarter ended June 28, 2026), up 9.4% from the same quarter a year earlier. That came with a gross margin of 66% and net income of $207M (18% of revenue). For the full year FY2025, revenue was $4.34B (−0.7% year on year) and net income $850M. Its largest region in 2026-Q1 was United States And Canada at $590M, 54% of the disclosed total, just ahead of EMEA at 33%.

Raw charts

11 series · TTM

As reported to the SEC, without any scoring.

Diagnostics & Research

Ranks #21 of 29 by Smart Score